[
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81",
    "summary": "Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...",
    "url": "https://finnhub.io/api/news?id=d5170e110bf58316c7ed7c2381736c0945011b7817e2c5a487240af61a9305cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733423692,
      "headline": "Merck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81",
      "id": 131802677,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...",
      "url": "https://finnhub.io/api/news?id=d5170e110bf58316c7ed7c2381736c0945011b7817e2c5a487240af61a9305cc"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c47afa602d73e389596b6b321b389818483976b4ad20cb0e726b1f44d6e8e257",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733416500,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 131874663,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c47afa602d73e389596b6b321b389818483976b4ad20cb0e726b1f44d6e8e257"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=0d0d44ede316dc4387bcef6d13664cf0a9c45b99187c039b3f3a74620f6f0b81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733407217,
      "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 131802678,
      "image": "https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=0d0d44ede316dc4387bcef6d13664cf0a9c45b99187c039b3f3a74620f6f0b81"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What is Powering Merck & Co.’s (MRK) Earnings Growth",
    "summary": "GreensKeeper Asset Management, an investment management company, released its third quarter investor letter. A copy of the letter can be downloaded here. The Value Fund appreciated +4.7% (net) in the third quarter, +16.7% year to date and +24.4% over the past twelve months, however, the US dollar lowered returns by about -1.1% in Q3. The […]",
    "url": "https://finnhub.io/api/news?id=0815634b3a16332b7e0e156e66f51ac5093bf86d21f887b96712a16d9f519592",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733402908,
      "headline": "Here’s What is Powering Merck & Co.’s (MRK) Earnings Growth",
      "id": 131802680,
      "image": "https://media.zenfs.com/en/insidermonkey.com/4c2d50f14c73c26f6188d27970ea7976",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GreensKeeper Asset Management, an investment management company, released its third quarter investor letter. A copy of the letter can be downloaded here. The Value Fund appreciated +4.7% (net) in the third quarter, +16.7% year to date and +24.4% over the past twelve months, however, the US dollar lowered returns by about -1.1% in Q3. The […]",
      "url": "https://finnhub.io/api/news?id=0815634b3a16332b7e0e156e66f51ac5093bf86d21f887b96712a16d9f519592"
    }
  },
  {
    "ts": null,
    "headline": "Merck : Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025",
    "summary": "December 5, 2024 11:53 am ET RAHWAY, N.J., Dec. 5, 2024 - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most...",
    "url": "https://finnhub.io/api/news?id=fb6e4f42cd6b7b8ffbb5ac2c4618f889916a6eddad90171f2ee3a3991a8b0a70",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733399764,
      "headline": "Merck : Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025",
      "id": 131794272,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "December 5, 2024 11:53 am ET RAHWAY, N.J., Dec. 5, 2024 - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most...",
      "url": "https://finnhub.io/api/news?id=fb6e4f42cd6b7b8ffbb5ac2c4618f889916a6eddad90171f2ee3a3991a8b0a70"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults",
    "summary": "RAHWAY, N.J. & MIAMI, December 05, 2024--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults",
    "url": "https://finnhub.io/api/news?id=be0146cff961fd038a9426b477250dba814027c7aa400a0317374fdd9ddb82f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733399100,
      "headline": "Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults",
      "id": 131802682,
      "image": "https://media.zenfs.com/en/business-wire.com/3c05fd5249cb8ba719a97f851a292957",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & MIAMI, December 05, 2024--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults",
      "url": "https://finnhub.io/api/news?id=be0146cff961fd038a9426b477250dba814027c7aa400a0317374fdd9ddb82f6"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)",
    "summary": "Merck &amp; Co. Inc.",
    "url": "https://finnhub.io/api/news?id=839c15ad3f8e3d7e96f017150d644d6186299bad83582825d83ac36a5fbc3821",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733396346,
      "headline": "Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)",
      "id": 131793218,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck &amp; Co. Inc.",
      "url": "https://finnhub.io/api/news?id=839c15ad3f8e3d7e96f017150d644d6186299bad83582825d83ac36a5fbc3821"
    }
  },
  {
    "ts": null,
    "headline": "Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025",
    "summary": "RAHWAY, N.J. /3BL/ - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most Responsible Companies for the second year in a row.We...",
    "url": "https://finnhub.io/api/news?id=7034d29d1a917f960f7be3e22b4c4e2d4536b45e9d58cffaaa4e426c88461657",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733395511,
      "headline": "Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025",
      "id": 131792917,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY, N.J. /3BL/ - Merck , known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most Responsible Companies for the second year in a row.We...",
      "url": "https://finnhub.io/api/news?id=7034d29d1a917f960f7be3e22b4c4e2d4536b45e9d58cffaaa4e426c88461657"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Phase III trial of Covid-19 begins",
    "summary": "Merck announced on Thursday the start of a Phase 3 study to assess the efficacy of its Lavegrio tablet in the treatment of Covid-19 in patients at risk of disease progression.The double-blind,...",
    "url": "https://finnhub.io/api/news?id=f294257691a5fbcce835480d3069cac0dfca7e572270f2da5dc0e47c8bcbb365",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733387056,
      "headline": "Merck: Phase III trial of Covid-19 begins",
      "id": 131791289,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced on Thursday the start of a Phase 3 study to assess the efficacy of its Lavegrio tablet in the treatment of Covid-19 in patients at risk of disease progression.The double-blind,...",
      "url": "https://finnhub.io/api/news?id=f294257691a5fbcce835480d3069cac0dfca7e572270f2da5dc0e47c8bcbb365"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Flexible Capital Income Fund Q3 2024 Commentary",
    "summary": "Columbia Flexible Capital Income Fund Institutional Class shares returned 8.25% in the \nthird quarter ending September 30, 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=c03ef79a687d79d6ea10becab6b077639c850f6fda9a6457e91141649f42db18",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733361600,
      "headline": "Columbia Flexible Capital Income Fund Q3 2024 Commentary",
      "id": 131774908,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Columbia Flexible Capital Income Fund Institutional Class shares returned 8.25% in the \nthird quarter ending September 30, 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=c03ef79a687d79d6ea10becab6b077639c850f6fda9a6457e91141649f42db18"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Dividend Opportunity Fund Q3 2024 Commentary",
    "summary": "Institutional Class shares of Columbia Dividend Opportunity Fund returned 9.51% for the \nthird quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=e4db43d07b7e4e8068187a3bf164970512789db26f6e7a3289ddcfb4a5000d38",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733357700,
      "headline": "Columbia Dividend Opportunity Fund Q3 2024 Commentary",
      "id": 131773941,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283813790/image_1283813790.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Institutional Class shares of Columbia Dividend Opportunity Fund returned 9.51% for the \nthird quarter. Click here to read the full commentary. \n",
      "url": "https://finnhub.io/api/news?id=e4db43d07b7e4e8068187a3bf164970512789db26f6e7a3289ddcfb4a5000d38"
    }
  }
]